<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation of the patient with suspected malignancy-related ascites</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation of the patient with suspected malignancy-related ascites</h1>
<div class="graphic"><div class="figure"><div class="ttl">Evaluation of the patient with suspected malignancy-related ascites</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr class="divider_bottom border_bottom_thick"> <td colspan="6"><strong>Select</strong> the target population: <ul class="decimal_heading"> <li>Patients with ascites and suspected or established malignancy*</li> </ul> </td> </tr> <tr class="divider_bottom divider_top border_bottom_thick"> <td colspan="6"><strong>Perform</strong> the following studies: <ul class="decimal_heading"> <li>Diagnostic paracentesis<sup>¶</sup><sup>Δ</sup></li> <li>Serum albumin</li> <li>Abdominal imaging (eg, computed tomography scan, magnetic resonance imaging)</li> </ul> </td> </tr> <tr class="divider_bottom divider_top"> <td colspan="6"><strong>Determine</strong> likely etiology for ascites:</td> </tr> <tr class="divider_bottom"> <td><strong>Diagnosis</strong></td> <td><strong>Fluid cell count</strong><sup>◊</sup></td> <td><strong>Fluid total protein</strong></td> <td><strong>High fluid triglyceride level</strong><sup>§</sup></td> <td><strong>Fluid cytology</strong></td> <td><strong>Imaging features</strong></td> </tr> <tr> <td class="indent1" colspan="6"><strong>SAAG &lt;1.1 g/dL</strong><sup>¥</sup></td> </tr> <tr> <td class="indent2">Peritoneal carcinomatosis</td> <td>High with predominantly lymphocytes</td> <td>≥2.5 g/dL</td> <td>No</td> <td>Positive<sup>‡</sup></td> <td>Peritoneal and omental implants</td> </tr> <tr> <td class="indent2">Malignancy-related chylous ascites</td> <td>High with predominantly lymphocytes</td> <td>≥2.5 g/dL</td> <td>Yes</td> <td>Negative</td> <td>Abdominal lymphadenopathy</td> </tr> <tr> <td class="indent1" colspan="6"><strong>SAAG ≥1.1 g/dL</strong><sup>¥</sup></td> </tr> <tr> <td class="indent2">Massive liver metastases with portal hypertension</td> <td>Low</td> <td>&lt;2.5 g/dL</td> <td>No</td> <td>Negative</td> <td>&gt;50% liver replacement by tumor</td> </tr> <tr> <td class="indent2">Hepatocellular carcinoma with cirrhosis</td> <td>Low</td> <td>&lt;2.5 g/dL</td> <td>No</td> <td>Negative</td> <td>Focal lesion(s) in cirrhotic liver<sup>†</sup></td> </tr> <tr> <td class="indent2">Malignancy-related Budd-Chiari syndrome</td> <td>Low</td> <td>Variable</td> <td>No</td> <td>Negative</td> <td>Extrinsic tumor compression causing narrowing and/or thrombus of the hepatic vein</td> </tr> </tbody></table></div><div class="graphic_lgnd">Refer to UpToDate content on the evaluation and management of malignancy-related ascites.</div><div class="graphic_footnotes">SAAG: serum-to-ascites albumin gradient.<br/>* Ascites typically develops in the setting of recurrent and/or advanced cancer. Malignancies of ovarian and urinary bladder origin tend to cause isolated peritoneal carcinomatosis without liver metastases. The most common tumor types causing peritoneal carcinomatosis with liver metastases are colon, gastric, breast, pancreatic, and lung cancers.<br/>¶ The following tests are routinely performed on ascitic fluid when malignancy-related ascites is suspected: Gram stain, aerobic and anaerobic culture, cell count and differential, albumin, total protein, glucose, triglyceride level, cytology.<br/>Δ For patients with suspected malignancy-related ascites, diagnostic paracentesis is performed if it will contribute to the evaluation and/or management.<br/><span class="lozenge">◊</span> A high ascitic fluid white blood cell count is defined as ≥500 cells/mm<sup>3</sup>.<br/>§ For patients with chylous ascites, fluid triglyceride level is typically above 200 mg/dL.<br/>¥ The SAAG is calculated by subtracting the ascitic fluid albumin value (in g/dL) from the serum albumin value (in g/dL).<br/>‡ For patients with suspected peritoneal carcinomatosis (eg, based on imaging findings) but with negative initial fluid cytology, repeat paracentesis with fluid cytology is warranted.<br/>† For patients at risk for developing hepatocellular carcinoma (eg, those with cirrhosis), the diagnosis can be made with contrast-enhanced computed tomography or magnetic resonance imaging tailored for liver evaluation. Refer to other UpToDate content on diagnosis of hepatocellular carcinoma.</div><div id="graphicVersion">Graphic 126221 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
